Vimta Labs Limited has informed the Exchange about Transcript
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vimta Labs reported FY25 revenue of INR 3,482 million, up 19.1% YoY, with EBITDA of INR 1,262 million (up 29.1%) and PAT of INR 668 million (up 36.8%); EBITDA margin stood at 36.2% and PAT margin at 19.2%. Q4 FY25 revenue grew 31.4% YoY to INR 961 million with EBITDA margin of 36.1%. The company remains net debt-free with cash and deposits of INR 329 million and a debt-to-equity ratio of 0.02x. Management announced a new foray into biologics contract R&D services involving an additional INR 40 crore investment over two years, with revenue expected from Q1 FY27. FY26 capex guidance is around INR 90 crore (excluding biologics), and management targets an INR 125 crore quarterly revenue run rate by Q4 FY26.
Strong FY25 results with margin expansion and net debt-free status reinforce the company's financial health, while the new biologics CDMO foray signals a meaningful growth lever from FY27 onwards. The INR 500 crore run rate target by Q4 FY26 and stable margin guidance could support positive investor sentiment, though near-term returns from the biologics investment will be delayed.